Aktis Oncology, Inc.
AKTS
Sync financial data to generate a health grade for this company.
Analytical Summary
Review the statement evidence below to form a view on AKTS.
4-Year Financial Trajectory
QuarterlyStatement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-Q ↗ |
|---|---|---|---|---|
| Revenue Growth YoY (%) |
123.0%
Excellent
Excellent
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Above avg (+1438%)
|
— | — | — |
| EPS Growth YoY (%) |
98.0%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — | — |
| Net Income Growth YoY (%) |
-22.3%
Weak
Weak
Year-over-year change in net income |
— | — | — |
| FCF Growth YoY (%) |
97.8%
Excellent
Excellent
Year-over-year change in free cash flow |
— | — | — |
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-Q ↗ |
|---|---|---|---|---|
| FCF / Net Income (x) |
1.42x
Good
Good
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
1.29x
Good
Good
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-Q ↗ |
|---|---|---|---|---|
| Return on Invested Capital (%) |
-3.5%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
14.1%
Good
Good
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-3.9%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— | — | — |
| Return on Common Equity (%) (%) |
-3.6%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-124%)
|
— |
14.8%
Fair
Fair
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
At sector avg
|
— |
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-Q ↗ |
|---|---|---|---|---|
| Sales/Revenue/Turnover (USD) | $3.23M | — | $1.45M | — |
| Depreciation Expense (USD) | $652.00K | — | $484.00K | — |
| Net Income, GAAP (USD) | $-18.32M | — | $-14.98M | — |
| Operating Cash Flow (USD) | $-24.24M | — | $-17.48M | — |
Secondary lens
Benchmark Lens
Compare AKTS against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare AKTS against peers after checking the statement evidence.
Compare AKTS with peers
Stack AKTS against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago